News Archive

2021

June

Media Release / Jun 04, 2021

Novartis investigational checkpoint inhibitor tislelizumab met primary endpoint of overall survival in pivotal Phase III trial of esophageal cancer after systemic therapy

Read More
Media Release / Jun 04, 2021

Novartis announces Tabrecta® first published overall survival and updated overall response data in patients with METex14 metastatic NSCLC

Read More
Media Release / Jun 02, 2021

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Read More
Media Release / Jun 02, 2021

Novartis Kisqali® reports longest median overall survival in postmenopausal HR+/HER2- metastatic breast cancer patients

Read More
Media Release / Jun 01, 2021

Novartis Cosentyx receives FDA approval for treatment of children and adolescents with moderate to severe plaque psoriasis

Read More

May

Media Release / May 28, 2021

Novartis reports one year results of Phase III MERLIN study evaluating BEOVU® every four week dosing and provides update on BEOVU clinical program

Read More
Media Release / May 26, 2021

Novartis commits to addressing racial disparities in breast cancer screening, treatment and care

Read More
Media Release / May 01, 2021

Novartis Phase III BEOVU® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

Read More

April

Media Release / Apr 23, 2021

Novartis Cosentyx® data at AAD VMX shows improvement in skin symptoms and quality of life was maintained up to one year in children with moderate to severe plaque psoriasis

Read More
Media Release / Apr 16, 2021

Kesimpta® (ofatumumab) data at AAN showed reduction in disability progression independent of relapse activity in newly diagnosed patients with RMS

Read More

Related Links